Page 9 - Johnson & Johnson

Johnson & Johnson wins trial over California man's talc-cancer claims

J&J is facing more than 13,000 lawsuits linking baby powder and another talc product

Does J&J's 'No More Tears' baby shampoo contain cancer-causing substance?

Rajasthan's drug controller found that Johnson & Johnson baby shampoo samples were not of standard quality

J&J's baby shampoo samples are not of standard quality: Drug controller

This comes after J&J's hip implants and baby powder were declared defective

Govt order asking J&J to pay compensation is complete hogwash: Expert

In November, the government had come up with a compensation formula based on factors such as age, risk and percentage of disability

US court awards $29 mn to cancer victim who alleged J&J talcum had asbestos

(Reuters) - A California jury on Wednesday awarded $29 million to a woman who said that asbestos in Johnson & Johnson's talcum-powder-based products caused her cancer.

J&J asked to pay Rs 74.5 lakh to first patient with faulty hip implant

Based on the recommendations of the central expert committee and the state-level committee, the Central Drugs Standard Control Organisation (CDSCO) has directed Johnson and Johnson to pay Rs 74,57,180 to the first patient from Mumbai who received faulty hip implants made by the company. This is the first case where M/s Johnson & Johnson has been directed to pay compensation for its faulty ASR hip implants manufactured and imported by M/s DePuy International Limited (now Johnson & Johnson Pvt Ltd). The CDSCO has directed the compensation to be paid within 30 days from the date of receipt of the order. In November last year, the Union Health Ministry approved a formula for determination of compensation for patients who had received, prior to August 2010, ASR hip implants manufactured by DePuy International Limited, U.K of J&J. According to the formula, thousands of patients implanted with US pharmaceutical major Johnson and Johnson's (J&J) articular surface replacement ..

Govt directs J&J to pay Rs 74 lakh to first victim of faulty hip implant

The expert committee had earlier suggested that patients should be paid based on the disability caused

J&J to add prices to TV ads making drug prices transparent for consumers

CHICAGO (Reuters) - Johnson & Johnson said on Thursday it will start adding the price of its medicines to television commercials by next month, becoming the first drugmaker to heed a call by U.S. President Donald Trump for price transparency of drugs advertised directly to consumers on TV.

$120 mn: Cost Johnson & Johnson will pay to settle hip-implant claims in US

(Reuters) - Johnson & Johnson and its DePuy Orthopaedics unit have agreed to pay $120 million to resolve deceptive marketing claims by several U.S. states over the company's metal-on-metal hip implants.

SC accepts govt response on compensation for J&J hip implant victims

Panel had recommended compensation of up to Rs 1.22 crore for victims

Take action against J&J over faulty hip implants: 10 MPs write to Nadda

Ten MPs, seven of them belonging to BJP ally Shiv Sena, have written to Union Health Minister J P Nadda to take "appropriate action" against global healthcare major Johnson and Johnson (J&J) and "ensure justice for all sufferers" of faulty ASR hip implants. Union Minister of State for Health and Family Welfare Anupriya Patel, who belongs to BJP ally Apna Dal(Sonelal), is among the 10 MPs to have written to Nadda. "Most recently, the company (J&J) seems to be going against the government's directions and denying its liability in compensating patients," Chandrakant Khaire, Shiv Sena MP from Aurangabad in Maharashtra, wrote in a letter dated January 7. "I call upon you 'sir' (Nadda) to independently identify all patients who have received the faulty ASR implants in India; and take appropriate action/s against the company to ensure that justice is met to all the sufferers of these faulty ASR (hip) implants (sic)," Khaire added. In December last year, J&J had approached the ...

India orders Johnson & Johnson to stop using raw material for Baby Powder

US company asked to stop using the 'huge quantities' of raw materials stocked in its plants in northern and western India.

J&J says talc powder in India safe, drug regulators visited plants

Regulators in India launch an investigation into Johnson & Johnson's Baby Powder following report that the firm knew for decades that cancer-causing asbestos lurked in the product.

Drug regulator to test samples of J&J baby powder over asbestos claims

NEW DELHI (Reuters) - India's drug regulator will on Wednesday seize samples of Johnson & Johnson's baby powder for testing, local media said, following a Reuters report that the company knew for decades that cancer-causing asbestos lurked in the product.

'Science. not sensationalism', J&J moves to weather the storm on powder row

J&J shares fell nearly 3% Monday. That drop was on top of the 10% plunge that wiped out about $40 billion of the company's market capitalization following the Reuters report

J&J plans $5 bn share buyback after report wipes out $50 bn in market value

(Reuters) - Johnson & Johnson said on Monday it plans to buy back up to $5 billion of its stock, after a Reuters report on Friday that the company knew for decades that its Baby Powder contained cancer-causing asbestos wiped about $40 billion from its market value.

J&J shares extend losses on reports of asbestos in baby powder

(Reuters) - Shares of Johnson & Johnson slipped another 2 percent on Monday, extending losses following Friday's Reuters report that the healthcare conglomerate knew for decades that cancer-causing asbestos lurked in its Baby Powder.

Johnson & Johnson's intraday plunge over 'asbestos report' wipes out $45 bn

The last time shares of Johnson & Johnsons came under this much pressure was due to asbestos concerns back in February

Johnson & Johnson is willing to pay $400 million-plus in hip-device cases

Company seeks end to Pinnacle hip suits before January trial

J&J implant case: Govt confident of making MNC compensate affected patients

The central government expects to make a legally convincing case on making Johnson & Johnson compensate people for its faultily made hip implants.The multinational company has petitioned the high court at Delhi to argue it is not liable to pay. However, a public interest suit to compel it is pending before the Supreme Court (SC). "Our Drugs and Cosmetics Act did not have a provision for compensation. J&J's main contention is that there is no provision under current law to compensate patients. We have already taken steps to plug the gap. Globally, J&J is paying affected patients, mostly through litigation or out-of-court settlements. There is no reason why they will not compensate the Indian patients," say senior health ministry sources.The implants manufactured by J&J's wholly-owned subsidiary, DePuy International, were faulty, and several instances of revision surgeries were reported in India and across the globe.The laws in several other countrues, said one official